眶部放疗治疗Graves眼病的前瞻性随机双盲安慰剂对照研究
6个月时各主要指标在放疗眼与未放疗眼间均无临床或统计学显著差异;12个月时先放疗眼肌肉体积与突眼度略改善,但临床意义有限。结论为未能证明放疗对GO的获益疗效。
要点
- 6个月时放疗眼与假照射眼在眼球突出、眼外肌体积、复视等主要指标上无显著差异。
- 12个月时先放疗眼的肌肉体积和突眼度略优于另一眼,但改善幅度临床意义有限。
- 作者认为12个月双眼的轻微改善可能源于自然缓解,不能确证放疗疗效。
核心结论
- 在该组常被推荐放疗的GO患者中,未能证明放疗具有任何获益的治疗效果。
- 12个月时双眼均见轻微改善,可能为自然缓解或放疗所致,但变化临床意义有限。
研究设计与样本
- 前瞻性、随机、内部对照、双盲临床试验,在三级学术医疗中心开展。
- 患者为30岁以上、种族多样的男性与女性,来自转诊实践,患中度症状性GO(平均临床活动度评分6.2)。
- 排除视神经病变、糖尿病、近期使用激素、既往减压手术或眼外肌手术者。
- 随机选择一眼接受20 Gy外照射,另一眼接受假照射,6个月后治疗互换。
主要发现
- 6个月时,在任一主要结局指标上,放疗眼与未放疗眼之间均无临床或统计学显著差异。
- 12个月时,先接受放疗的眼眶在肌肉体积和眼球突出方面改善略多。
- 每3个月随访1年,测量眼外肌与脂肪体积、眼球突出度、眼外肌运动范围、复视视野面积和睑裂宽度。
临床怎么用
- 本研究结果不支持对类似入组条件的中度症状性GO患者常规推荐眶部放疗。
- 临床决策时应向患者说明放疗在该人群未见显著获益,并考虑自然缓解的可能。
局限性
- 原文未报告具体P值、置信区间及效应量,无法量化差异大小。
- 随访仅1年,缺乏更长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Although widely used for more than 85 years, the efficacy of radiotherapy for Graves' ophthalmopathy (GO) has not been established convincingly. OBJECTIVE: To evaluate the efficacy of radiotherapy for GO. DESIGN: Prospective, randomized, internally controlled, double-blind clinical trial in a tertiary care academic medical center. PARTICIPANTS: The patients were ethnically diverse males and females over age 30 seen in a referral practice. The patients had moderate, symptomatic Graves' ophthalmopathy (mean clinical activity score, 6.2) but no optic neuropathy, diabetes, recent steroid treatment, previous decompression, or muscle surgery. Forty-two of 53 consecutive patients were enrolled after giving informed consent and fulfilling study entry criteria. Eleven eligible patients declined to participate because of inconvenience, desire for alternative therapy, or concern about radiation. INTERVENTION: One randomly selected orbit was treated with 20 Gy of external beam therapy; sham therapy was given to the other side. Six months later, the therapies were reversed. MAIN OUTCOME MEASURES: Every 3 months for 1 year, we measured the volume of extraocular muscle and fat, proptosis, range of extraocular muscle motion, area of diplopia fields, and lid fissure width. Effective treatment for GO will modify one or more of these parameters. RESULTS: No clinically or statistically significant difference between the treated and untreated orbit was observed in any of the main outcome measures at 6 months. At 12 months, muscle volume and proptosis improved slightly more in the orbit that was treated first. CONCLUSIONS: In this group of patients, representative of those for whom radiotherapy is frequently recommended, we were unable to demonstrate any beneficial therapeutic effect. The slight improvement noted in both orbits at 12 months may be the result of natural remission or of radiotherapy, but the changes are of marginal clinical significance.
引用
- Gorman CA, Garrity JA, Fatourechi V, et al. A Prospective, Randomized, Double-blind, Placebo-controlled Study of Orbital Radiotherapy for Graves' Ophthalmopathy. Ophthalmology. 2020. PMID: 32200817. doi:10.1016/j.ophtha.2020.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。